NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Authors :: Ettinger DS
Wood DE
Akerley W
Bazhenova LA
Borghaei H
Camidge DR
Cheney RT
Chirieac LR
D'Amico TA
Dilling T
Dobelbower M
Govindan R
Hennon M
Horn L
Jahan TM
Komaki R
Lackner RP
Lanuti M
Lilenbaum R
Lin J
Loo BW Jr
Martins R
Otterson GA
Patel JD
Pisters KM
Reckamp K
Riely GJ
Schild SE
Shapiro TA
Sharma N
Swanson SJ
Stevenson J
Tauer K
Yang SC
Gregory K
Hughes M
Source :: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2016 Jul; Vol. 14 (7), pp. 825-36.
Publication Year :: 2016
Abstract: These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.<br /> (Copyright © 2016 by the National Comprehensive Cancer Network.)